- 期刊
Randomized, Double-blind, Placebo-controlled, Comparative Study of Human Anti-TNF Antibody Adalimumab in Combination with Methotrexate and Methotrexate Alone in Taiwanese Patients with Active Rheumato
並列摘要
Background/Purpose: Adalimumab is a fully humanized monoclonal antibody that blocks tumor necrosis factor (TNF)-α, which is effective in the treatment of patients with rheumatoid arthritis (RA). The purpose of this study was to compare the efficacy and safety of adalimumab plus methotrexate (MTX) and MTX alone in Taiwanese patients with active RA. Methods: Forty-seven patients with active RA who were maintained on MTX therapy at a stable dose of 10-15 mg/week for 4 weeks were randomized blindly to receive adalimumab 40 mg (n=35) or placebo (n=12) by subcutaneous injection every other week over a period of 12 weeks. The primary endpoint was a reduction in tender and swollen joint counts of 20% (ACR20), 50% (ACR50) and 70% (ACR70), as determined by the American College of Rheumatology criteria in week 12. The occurrence of treatmentemergent adverse events (TEAEs) was the primary safety variable. Results: Addition of adalimumab to MTX resulted in a significant reduction in the number of swollen joints (12.6 vs. 5.6; p=0.011), patients' global assessment of disease activity (18.0 vs. 4.8; p=0.040), pain visual analog scale (18.3 vs. 1.3; p=0.015), and disability indices of the Health Assessment Questionnaire (0.6 vs. 0.2; p=0.031), compared with MTX alone after 12 weeks of therapy. Overall improvement in disease activity was assessed by ACR20 (54.3% vs. 33.3%), ACR50 (34.3% vs. 16.7%) and ACR70 (14.3% vs. 0%), and all favored the adalimumab plus MTX group. TEAEs were comparable between the treatment groups, except for a slightly higher incidence of severe infection in the adalimumab plus MTX group. Conclusion: Adalimumab in combination with MTX is well tolerated and provides significantly more clinical benefits than MTX alone in Taiwanese patients with active RA.
被引用紀錄
延伸閱讀
- Hammoudeh, M., Awadhi, A. A., Hasan, E. H., Akhlaghi, M., Ahmadzadeh, A., & Abdollahi, B. S. (2015). Safety, Tolerability, and Efficacy of Tocilizumab in Rheumatoid Arthritis: An Open-Label Phase 4 Study in Patients from the Middle East. International Journal of Rheumatology, 2015(), 136-142. https://doi.org/10.1155/2015/975028
- Lai, C. C., Lee, L. N., Yu, C. J., Hsueh, P. R., Yang, P. C., Kuo, S. H., & Luh, K. T. (2007). Antibody Responses to Pneumococcal Polysaccharide Vaccine in Taiwanese Patients with Chronic Obstructive Pulmonary Disease. Journal of the Formosan Medical Association, 106(3), 196-203. https://doi.org/10.29828/JFMA.200703.0015
- Shahin, D., Toraby, E. E., Malek, H. A., Boshra, V., Elsamanoudy, A. Z., & Shaheen, D. (2011). Effect of Peroxisome Proliferator-Activated Receptor Gamma Agonist (Pioglitazone) and Methotrexate on Disease Activity in Rheumatoid Arthritis (Experimental and Clinical Study). Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders, (2011), 1-10. https://doi.org/10.4137/CMAMD.S5951
- Hsiao, C. Y., Chang, C. T., Chen, Y. F., & Yu, K. H. (2021). The Impact of Antiphospholipid Antibody Profile on the Clinical Outcomes Associated with Systemic Lupus Erythematosus in Taiwanese Patients. Formosan Journal of Rheumatology, 35(1), 17-27. https://doi.org/10.6313/FJR.202106_35(1).0003
- Chi, K. H., Chang, K. H., Chen, S. T., Yen, S. H., & Lasi, Y. L. (2007). A Double-blinded, Placebo-controlled Study to Evaluate the Efficacy and Safety of Oral Pilocarpine for Treatment of Post-irradiation Xerostomia in Taiwanese Patients with Head and Neck Cancer. 馬偕護理雜誌, 1(2), 41-47. https://doi.org/10.29415/JMKN.200707_1(2).0005